Pipeline Snapshot
 |
|---|
| KIND-030 – Parvovirus in dogs
|
| Tirnovetmab (IL31 Antibody) – Atopic dermatitis in dogs
|
| Long-acting IL-31 antibody – Atopic dermatitis in dogs
|
| Anti-TNFα Antibody – Inflammatory bowel disease in dogs
|
| IL4R Antibody – Atopic dermatitis in dogs
|
Other pipeline candidates in development (partial list) include KIND-bodies, IgE antibody, CD20 antibody, VEGF antibody, and Checkpoint Inhibitors.
Pipeline Disclaimer: This material is intended to provide investors with information about KindredBio’s clinical development pipeline and is not intended for promotional purposes.
Our dogs look to us.
Dogs suffer from many of the same diseases that humans do, including allergic, inflammatory, and autoimmune diseases, as well as cancer. We have a deep pipeline of innovative biologics in development specifically for dogs, their owners, and the veterinarians that care for them.
US-CORP-1900168 FEB-20